Quick Answer
IMMUNIC, INC. reported Net Income of -$97.17 million for fiscal year 2025.
IMMUNIC, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$97.17M +3.3% |
-$100.51M -7.4% |
-$93.61M +22.3% |
-$120.41M -29.5% |
-$92.94M -111.2% |
-$44.02M -26.0% |
| Diluted EPS | -$0.62 +38.0% |
-$1.00 +52.6% |
-$2.11 +44.2% |
-$3.78 +3.8% |
-$3.93 -39.9% |
-$2.81 |
| Total Assets | $24.05M -41.1% |
$40.87M -24.7% |
$54.30M -57.5% |
$127.75M -8.2% |
$139.10M -17.1% |
$167.86M +154.5% |
| Cash and Equivalents | $15.48M -56.6% |
$35.67M -23.6% |
$46.67M -56.3% |
$106.75M +22.9% |
$86.86M -31.8% |
$127.45M +334.0% |
| Stockholders Equity | -$6.67M -136.2% |
$18.43M -36.3% |
$28.93M -74.6% |
$113.68M -10.6% |
$127.11M -19.9% |
$158.78M +172.1% |
| R&D Expense | $81.98M +2.4% |
$80.05M -3.8% |
$83.22M +16.8% |
$71.25M +16.6% |
$61.12M +58.2% |
$38.64M +71.6% |
| Operating Income | -$103.23M -5.3% |
-$98.05M +1.2% |
-$99.22M +17.0% |
-$119.49M -30.4% |
-$91.67M -87.2% |
-$48.97M -32.2% |
| Shares Outstanding | 90.15M +0.0% |
90.15M +99.5% |
45.18M +14.9% |
39.31M +49.3% |
26.34M +24.4% |
21.17M +97.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$25.58M | -5.0% | +4.6% |
| Diluted EPS | September 30, 2025 | -$0.13 | +45.8% | +35.0% |
| Total Assets | September 30, 2025 | $40.70M | -37.1% | -33.7% |
| Cash and Equivalents | September 30, 2025 | $35.13M | -40.5% | -36.5% |
| Stockholders Equity | September 30, 2025 | $10.50M | -74.5% | -69.0% |
| R&D Expense | September 30, 2025 | $20.01M | -6.4% | -6.4% |
| Operating Income | September 30, 2025 | -$25.99M | -1.0% | +4.0% |
| Shares Outstanding | September 30, 2025 | 98.65M | +9.5% | +0.0% |
- IMMUNIC, INC. reported Net Income of -$97.17 million for fiscal year 2025.
- IMMUNIC, INC. showed an increase of +3.3% in Net Income compared to the prior fiscal year.
- IMMUNIC, INC. reported Diluted EPS of $0.62 per share (loss) for fiscal year 2025.
- IMMUNIC, INC. showed an increase of +38.0% in Diluted EPS compared to the prior fiscal year.
- IMMUNIC, INC. reported Total Assets of $24.05 million for fiscal year 2025.
- IMMUNIC, INC. showed a decrease of -41.1% in Total Assets compared to the prior fiscal year.
- IMMUNIC, INC. reported Cash and Equivalents of $15.48 million for fiscal year 2025.
- IMMUNIC, INC. showed a decrease of -56.6% in Cash and Equivalents compared to the prior fiscal year.
- IMMUNIC, INC. reported Stockholders Equity of -$6.67 million for fiscal year 2025.
- IMMUNIC, INC. showed a decrease of -136.2% in Stockholders Equity compared to the prior fiscal year.
- IMMUNIC, INC. reported R&D Expense of $81.98 million for fiscal year 2025.
- IMMUNIC, INC. showed an increase of +2.4% in R&D Expense compared to the prior fiscal year.
- IMMUNIC, INC. reported Operating Income of -$103.23 million for fiscal year 2025.
- IMMUNIC, INC. showed a decrease of -5.3% in Operating Income compared to the prior fiscal year.
- IMMUNIC, INC. reported Shares Outstanding of 90.15 million shares for fiscal year 2025.
- IMMUNIC, INC. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: